Asian Journal of Biological and Life Sciences logo
Article

Evaluating Pharmacologic Interventions in Multiple System Atrophy with Predominant Parkinsonism: A Case Report

1, 1, 1, 1, 1, 1

  1. 1Department of Pharmacy Practice, Al Shifa College of Pharmacy, Keezhattur, Perinthalmanna, Malappuram, Kerala, INDIA.

CORRESPONDENCE

Sai Keerthana Puthiyedath Cheruvatta

Department of Pharmacy Practice, Al Shifa College of Pharmacy, Keezhattur, Perinthalmanna, Malappuram, Kerala, INDIA.

saikeerthana2022@gmail.com

Received: 12-10-2024; Revised: 14-11-2024; Accepted: 16-12-2024.

Volume 13, Issue 3 · pp. 890-893 · 2024 · DOI: 10.5530/ajbls.2024.13.107

ABSTRACT

Multiple System Atrophy (MSA) is a rare, progressive neurological disorder, more common in men, with an incidence of 0.1-3.0 per 100,000, typically emerging in people aged 50 to 60. The cause remains unknown and its pathology is marked by glial cytoplasmic inclusions and degeneration of the striatum and olivopontocerebellar regions. Multiple System Atrophy (MSA) can include symptoms such as problems with blood pressure control, movement, balance and coordination. MSA is often classified into two main types: MSA-P, primarily affecting movement and causing Parkinson’s-like symptoms and MSA-C, primarily affecting balance and coordination. A 78-year-old man with an underactive thyroid gland experienced a decline in cognitive function, difficulty controlling bladder function and movement problems such as slowness, shaking and falls. MRI findings of brain atrophy, gliosis and reduced blood flow supported an MSA-P diagnosis. Levodopa and other Parkinson’s medications were ineffective, indicating MSA-P’s poor response to dopaminergic treatment. Diagnosis and Management: MSA-P often mimics Parkinson’s disease but progresses more rapidly, shows poor levodopa response and presents with unique MRI markers. Enhanced diagnostic criteria and tools are needed, especially early in the disease. Treatments may ease symptoms but do not alter disease progression. Given the complexity of MSA-P and its severe prognosis (average survival <10 years), multidisciplinary management is essential for symptom control and quality of life improvement.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Cheruvatta, S. K. P., Pattambi, M. A., Koppara, M. I., Simon, P., Rajagopalan, N. S., & Sabith, A. (2024). Evaluating Pharmacologic Interventions in Multiple System Atrophy with Predominant Parkinsonism: A Case Report. Asian Journal of Biological and Life Sciences, 13(3), 890-893. https://doi.org/10.5530/ajbls.2024.13.107

    Copyright and licence

    © 2024 Author(s)

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. CC BY 4.0